CJ Cheiljedang Corporation (KRX:097950)
South Korea · Delayed Price · Currency is KRW | Market Cap | 3.21T -12.2% |
| Revenue (ttm) | 27.75T -5.5% |
| Net Income | -456.03B |
| EPS | -28,472.91 |
| Shares Out | 16.02M |
| PE Ratio | n/a |
| Forward PE | 8.11 |
| Dividend | 6,000.00 (2.84%) |
| Ex-Dividend Date | May 28, 2026 |
| Volume | 57,114 |
| Open | 211,000 |
| Previous Close | 211,000 |
| Day's Range | 204,500 - 211,000 |
| 52-Week Range | 186,100 - 270,000 |
| Beta | 0.25 |
| Analysts | Buy |
| Price Target | 273,250.00 (+32.65%) |
| Earnings Date | May 12, 2026 |
About CJ Cheiljedang
CJ Cheiljedang Corporation engages in the food business in South Korea and internationally. It operates through Food, Biotechnology, Feed and Care, and Logistics segments. The company offers home meal replacement, meat/fishery processing, seasoning/sauce, sweetener/flour/oil, and seaweed/dessert/snack/beverage products. It also provides amino acid, green protein, enzyme, plant nutrition and health, and specialty solution; biopolymer solution; and polyhydroxyalkanoate products. In addition, the company offers taste and nutrition solutions. Furth... [Read more]
Financial Performance
Financial StatementsNews
CJ Cheiljedang Q1 Operating Profit Declines
(RTTNews) - CJ Cheiljedang Corporation (097950.KS) reported first quarter net income attributable to shareholders of the parent company of 81.83 billion Korean won, a substantial increase of 363.8% co...
CJ Cheiljedang Earnings Call Transcript: Q1 2026
Q1 2026 saw sales growth across food, BIO, and logistics, but operating profit declined due to BIO price pressures. Q2 is expected to bring improved profitability, especially in BIO, with continued sales growth and margin recovery amid ongoing global expansion and cost challenges.
CJ Cheiljedang Slides: Q1 2026
CJ Cheiljedang has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 11, 2026.
CJ Cheiljedang Earnings Call Transcript: Q4 2025
Q4 2025 saw modest sales growth but a sharp drop in operating profit due to Bio business weakness and holiday timing. Global Food outperformed, while Bio faced intense competition and pricing pressure. 2026 guidance projects low single-digit sales growth and stable margins.
CJ Cheiljedang Annual report: Q4 2025
CJ Cheiljedang has published its Q4 2025 annual report on February 9, 2026.
CJ Cheiljedang Slides: Q4 2025
CJ Cheiljedang has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 9, 2026.
CJ Cheiljedang Earnings Call Transcript: Q3 2025
Q3 2025 saw a 1.9% year-over-year revenue decline (excluding logistics) due to bio and feed & care weakness, while food business showed resilience and global expansion. Operating profit and net profit dropped sharply, with ongoing margin pressure in bio and cost headwinds in food.
CJ Cheiljedang Slides: Q3 2025
CJ Cheiljedang has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 10, 2025.
CJ Cheiljedang Earnings Call Transcript: Q2 2025
Q2 2025 saw flat sales overall, with overseas food and bio growth offsetting domestic food weakness. Net profit rose 40% year-over-year, while operating profit declined due to higher costs and weak Korean demand. Q3 guidance projects low single-digit revenue growth and stable margins.
CJ Cheiljedang Slides: Q2 2025
CJ Cheiljedang has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 11, 2025.